RASSF1 and plasma cell myeloma: Intriguingly, another member of the RASSF family, RASSF4 re-expression has been shown to potentiate the effect of bortezomib in multiple myeloma cell lines when this drug is used in combination with MEK1/2 inhibitor [143], which indicates that the same might occur for RASSF1A.